Tag: PharmaceuticalIndustry
-
Lupin Receives USFDA Establishment Inspection Report for New Jersey Facility: A Positive Milestone Amidst Strong Financial Performance
Lupin has successfully received the Establishment Inspection Report (EIR) from the USFDA for its Somerset facility in New Jersey. This milestone highlights the company’s dedication to maintaining high-quality manufacturing standards and strengthens its position in global pharmaceutical markets.
-
Granules India Board Approves Acquisition of 100% Stake in Senn Chemicals AG for Rs 192.5 Crore
Granules India has announced its acquisition of Senn Chemicals AG, a Swiss CDMO specializing in peptide synthesis. This move strengthens Granules' position in the rapidly growing peptide therapeutics market, particularly in the development of next-generation anti-diabetic and anti-obesity treatments. The acquisition will enhance their R&D and manufacturing capabilities, driving innovation and expanding their global reach.
-
Orchid Pharma Gains 1.96% After Successful USFDA Inspection of Tamil Nadu Facility
Orchid Pharma’s recent USFDA inspection success and the renewal of its EU GMP certification have strengthened its position in the global pharmaceutical market. However, despite regulatory milestones, the company reported a decline in financial performance for Q3 FY25.
-
Piramal Alternatives Invests Rs 110 Crore in Biodeal Pharmaceuticals: A Strategic Boost for Innovation and Growth
Fueling Biodeal Pharmaceuticals' growth trajectory, Piramal Alternatives, the investment arm of the Piramal Group, has injected Rs 110 crore into the company. This strategic investment is poised to catapult Biodeal's capabilities, propelling it towards innovation, enhanced production, and expanded operations. With a focus on becoming a frontrunner in nasal spray manufacturing, Biodeal aims to leverage this infusion to fortify its infrastructure, adopt cutting-edge technology, and establish a state-of-the-art nutraceuticals facility. This collaboration signifies a significant milestone for both entities, marking a new chapter in the pharmaceutical landscape.